

Following the US Supreme Court ruling in <u>Dobbs (2022)</u>, many states began changing laws regarding reproductive health care rights. In the new reproductive environment created by this ruling, Americans who are concerned with family planning are showing greater interest in birth control options and are more likely to consume and practice the birth control methods (that remain legal) in greater numbers than before. Pfizer can capitalize on this trend by understanding public perceptions of the various methods and responding to these perceptions in their marketing.

In 2018, researchers Surya Kallumadi and Felix Gräßer at UC Irvine created the <u>UCI ML Drug Review</u>

<u>Dataset</u> after collecting reviews from <u>Drugs.com</u> that users had written about various drugs between 2008 and 2017. A substantial portion of these reviews addressed birth control and emergency contraception drugs.

People often share experiences and concerns with each other in online spaces such as Reddit and Quora, not exactly the same as they might in a drug review, but still using much of the same language. Our project analyzes the Drug Review Dataset in order to 1) learn what the Dataset can tell Pfizer about sentiments toward the various methods of birth control and 2) train a model that can be applied in other online spaces to determine what birth control methods users are discussing and how they feel about them. With this tool, Pfizer can more effectively market their products to the increased demand created by the Dobbs ruling.

## **Data Understanding**

After a substantial amount of cleaning, the data set included 21,779 records. Each record had these features:

### **Drug Name**

These labels varied greatly. Many were specific brand names, while others were generic or chemical names, or even combinations of chemical names.

### Condition

This feature had many missing labels. We eventually trimmed this feature to just two labels: "Birth Control" and "Emergency Contraception". In fact there was some cross-mixing of these two conditions, i.e. records labeled "Birth Control" that actually reviewed drugs for emergency contraception purposes and vice versa.

### Method (of Birth Control)

This feature was central to our analysis, but it was not provided in the original dataset. We had to construct it by matching the various brand drug name labels to their corresponding method of birth control. ChatGPT was instrumental in the process of gathering this data.


We do not consider emergency contraception pills to be in direct competition with the other methods of birth control, so this method label was sometimes included in analysis and visual displays when comparisons seemed useful or when confusion was possible and otherwise excluded.

#### Review

This feature was the text of the review that a user posted on drugs.com. There were a great deal of duplicate reviews, as explained further below.


### Rating

Users submitted a rating between 1 and 10 accompanying each review.




This shows the overall distribution of those ratings.

### Date



The records spanned from February 2008 to November 2017. The number of reviews surged in 2015.



The average ratings of the methods vary over time.

### **Useful Count (Upvotes)**

This feature counted the number of "upvotes" recorded by other users. This did not factor into our analysis. In further inquiry, it would be wise to note that the increase in the number of records from 2014 onward likely correlates with an increase in upvotes that does not necessarily reflect *better* reviews but simply *more* readers using the site and upvoting them. Any analysis of this feature should perhaps calculate upvotes as a percentage of the total upvotes during a certain timespan, such as a day or a month.

# **Data Preparation**


## Duplicates, drug names, and missing condition labels

The majority of the records were entered twice: once with a brand name in the drugName feature and once with a generic or chemical name. Some of these special pairs was missing its condition label. In these instances we were able to restore the missing condition labels (by matching them with their pairmate).

For the remaining missing condition labels, we assigned the label that most commonly corresponded with the drug name listed. For example, if a record specified a drug name of "Viagra" but had no condition label, we would assign it the condition of "Erectile Dysfunction", as that was the most common condition associated with Viagra. In this way we were able to confirm which of the records with missing labels were relevant to our analysis. Only after this process was complete could we drop all the records with condition labels other than "Birth Control" or "Emergency Contraceptive".


There were still more duplication instances beyond the special brand/generic pairs described earlier. This involved instances of the same review (unmistakably verbatim) appearing in multiple records, usually on the same day or within a day, and usually with differing numbers of upvotes. We assumed in these cases that the same user had posted a review multiple times. We merged these reviews into a single record and modified the usefulCount to reflect the *total* number of upvotes from all instances. In at least one case, a single representative date label had to be chosen arbitrarily from two options that were only one day apart.

# **Exploration**




This shows that the pill is the dominant method, and IUDs are the next most commonly used, while most other prescription methods are not very commonly used.

The common denominator for all the groups measured above is women who are at risk for unintended pregnancy (i.e. having intercourse but not intending pregnancy). The orange bar represents women who use non-prescription methods (e.g. condoms, withdrawal, rhythm method) and therefore must be attentive to the preventative measure every time they have sex. The red bar represents women who are most at risk for unintended pregnancy, engaging in sex but using no method at all. Both of these groups represent a large potential customer base.




This shows that some of the lesser used methods (vaginal rings and patches) enjoy quite favorable ratings. The pill is not especially highly rated. Injectables and implantables are rated the lowest of all methods.

Here is a direct comparison of the ratings for the patch and the pill (as a percentage of their overall ratings counts):




This gives an even clearer picture of how the patch dominates the pill in favorable / unfavorable ratings.

Here are word clouds of terms deemed important by TFIDF analysis to their positive and negative ratings. First the patch:




And the pill:




Some insights here: Users frequently speak *positively* about weight and body image issues (e.g. "weight", "breast") when reviewing patch methods. Users frequently refer to problems such as "acne" and "bleeding" in their negative reviews of pill methods. This juxtaposition of one method's positives against another's negatives may seem like pure <a href="https://cherry.org

# **Feature Engineering**

We derived several new features from the review feature. One of the more interesting results was the "nuanced words" feature. We determined which reviews included words like "but", "although", and "nevertheless" that indicated the reviewer was engaging in even-handed reasoning. It turned out that this was somewhat predictive of the review's rating, as seen below.



A feature that was likely helpful in the method prediction model was the "brand name mention" features. We grouped the drug brand names by birth control method and constructed features for each method, indicating whether any of the brands associated with that method were mentioned in the review feature of a record. The results are below.



It's not perfect, as reviews often mentioned brands associated with other methods, but this surely helped the method prediction model a great deal.

# **Modeling - Method Prediction**

### Metric

The method prediction model classifies records into 7 birth control method categories. There is significant class imbalance (ranging from 45% to 2%), and we wanted to distribute the weight somewhat evenly across classes so that the little classes didn't get ignored. For this reason we chose the F1-macro scoring metric. This metric balances precision and recall for each class and weighs each class equally.

## **Dummy Classifier (BASELINE)**

The dummy classifier did poorly, as expected.

### **Decision Tree**

The decision tree classifier improved on the baseline significantly, and the tuned version did even better.

## **Logistic Regression**

This model and its tuned version performed better than all the rest.

## **Summary of Model Performance**


We experimented with some other models as well, but none of the results were as relevant as the main three mentioned above.

Model	F1-macro	Accuracy
Dummy Classifier	0.14	27.3%
Decision Trees (rough)	0.82	87.2%
Decision Trees (tuned)	0.84	88.3%
Random Forest (rough)	0.59	83.3%
Random Forest (tuned)	0.59	83.3%
Logistic Regression (rough)	0.87	92.1%
Logistic Regression (tuned)	0.90	94.2%

# Confusion Matrix for Final Method Prediction Model — Tuned Logistic Regression

Below is the confusion matrix for the tuned logistic regression model.

# Confusion Matrix for Tuned Logistic Regression Model



### **Evaluation of Method Prediction Model**

Our final model is the tuned logistic regression model. It returns the highest F1-macro score (0.91), which was our primary scoring metric. The F1-macro score averages F1 scores for all classes, unweighted. A weighted score might have forsaken accuracy on smaller classes (e.g. patch) in favor of scoring better on larger classes, but we wanted our model to have a more even distribution. Its overall accuracy (94%) is very impressive. The confusion matrix shows the most erroneous labels (predictably) occurring in the largest class (pill); the only other somewhat significant confusion (<5%) occurs when IUDs are confused with implantables.

# **Modeling - Sentiment Prediction**

### Metric

The sentiment prediction model classifies records into positive or negative sentiments. For the purposes of this model, we removed records with a rating of 5.0 and used that as the separation point between positive and negative.

There is a class imbalance in this case of nearly 2:1. We chose ROC-AUC as our scoring metric. This metric is good at handling class imbalance.

## **Dummy Classifier (BASELINE)**

The dummy classifier did poorly, as expected.

### **Decision Tree**

The decision tree classifier improved on the baseline significantly, and the tuned version did even better.

## **Logistic Regression**

The untuned logistic regression model performed better than the others that came before. Tuning this model improved the ROC-AUC score a little and overall accuracy a lot. This came with a decrease in recall of negative sentiments, but the overall accuracy is enough to make the tuned model preferable.

## **Summary of Model Performance**


We experimented with some other models as well, but none of the results were as relevant as the main three mentioned above.

Model	ROC-AUC	Recall	Accuracy
Dummy Classifier	0.48	37.9%	54.0%
Decision Trees (rough)	0.69	55.2%	72.6%
Decision Trees (tuned)	0.75	80.5%	70.8%
Random Forest (rough)	0.92	61.3%	82.4%
Random Forest (tuned)	0.93	63.0%	83.1%
Logistic Regression (rough)	0.93	96.0%	77.2%
Logistic Regression (tuned)	0.95	91.3%	86.3%

### **Confusion Matrix for Final Sentiment Prediction Model**


Below is the confusion matrix for the tuned logistic regression model.

# Confusion Matrix for Tuned Logistic Regression Model



**ROC-AUC curve for Final Sentiment Prediction Model** 


Below is the ROC-AUC curve for the tuned logistic regression model.



# **Evaluation of Sentiment Prediction Model**

Our final model is again the tuned logistic regression model. It delivers the highest ROC-AUC score, which was our primary scoring metric. The overall accuracy of 86% is quite impressive given the class imbalance.

We also have the benefit of feature importances here. Here are the top 25 most important ones for the final model:



Although none of our engineered features appeared in the top 25 most important features for our final model, The "Nuanced Words Count" and the readability scores appeared in multiple other models' top 25 most important features. This suggests that certain composition styles can be indicative of the sentiment expressed. Unfortunately, the coefficients for these features were only captured in models that had all positive coefficients, so we are unable at this point to see which sentiment they were indicative of!

The feature importances do show that our choice to leave in common stop words such as "no" and "not" paid off in this model, as did our inclusion of bigrams.

## Recommendations

### 1. Consider developing and marketing a patch as an alternative to the pill

Users rate the patch quite highly, but it is used much less than the pill. There is room for growth here.

### 2. Emphasize favorable weight and body image effects of patch methods

Our word clouds and term importance analysis shows that users appreciate these aspects of the patch.

### 3. Abandon injectable product (Depo-Provera)

This method is not commonly used and not highly rated.

### 4. Apply our prediction models in online spaces

Look in spaces such as Reddit and Quora to gather updated data on public sentiment toward the various birth control methods.

# **Further Inquiry**

- Incorporate upvotes more into analysis and modeling
- Explore the possibility of a recommendation algorithm
- More feature engineering possibilities
  - whether words are in English (spelled correctly)
  - o use of emoticons
  - whether it uses slang sex terms versus technical language
- Analyze evidence of reviewers switching methods or brands
- Understand what went wrong with XGB reproducibility in the multiclass model
- Scrape new text from Reddit, Quora and apply modeling to it

# Links to PDFs

Find the notebook here

Find the presentation here

Find the github repository here

Find reproducibility notes and instructions to run the notebook here



#### Releases

No releases published Create a new release

### **Packages**

No packages published Publish your first package

### Languages

Jupyter Notebook 100.0%